The impact of rivaroxaban on primary hemostasis in patients with venous thrombosis

The impact of rivaroxaban on primary hemostasis in patients with venous thrombosis

Factor Xa inhibitors are safe and effective alternatives to warfarin, but several studies indicate that rivaroxaban may cause a different risk profile for bleeding. For instance, while the risk of major bleeding in general may be lower with rivaroxaban than for warfarin, the risk of gastrointestinal...

Full description

Bibliographic Details
Main Authors: Nina Haagenrud Schultz, Pål Andre Holme, Stine Bjørnsen, Carola Elisabeth Henriksson, Per Morten Sandset, Eva-Marie Jacobsen
Format: Article
Language:English
Published: Taylor & Francis Group 2020-01-01
Series:Platelets
Subjects:
platelet aggregation
p-selectin
rivaroxaban
von willebrand factor
Online Access:http://dx.doi.org/10.1080/09537104.2018.1557618

Similar Items

Similar Items